Regadenoson Anhydrous

Regadenoson Anhydrous

SCHEMBL20128455

CNC(=O)c1cnn(-c2nc(N)c3ncn([C@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA2A

The experimentally established mechanism targets of Regadenoson Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ADORA2A known ✓ P29274 14/20 1.00
ADORA3 P0DMS8 9/20 1.00
ADORA1 P30542 6/20 1.00
ADORA2B P29275 1/20 1.00
ADRA1A P35348 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Regadenoson Anhydrous SCHEMBL19387116 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A
Regadenoson Anhydrous SCHEMBL14131217 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A
Regadenoson Anhydrous SCHEMBL12958830 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A
Regadenoson Anhydrous SCHEMBL8925057 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A
Regadenoson Anhydrous SCHEMBL278152 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A
Regadenoson Anhydrous SCHEMBL13462149 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A
Regadenoson Anhydrous SCHEMBL15472806 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A
Regadenoson Anhydrous SCHEMBL6745611 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A
Regadenoson Anhydrous SCHEMBL21710782 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A
Regadenoson Anhydrous SCHEMBL2558796 1.00 ADORA2A (1.00) ADORA2AADORA3ADORA1ADORA2BADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392417-B2 Polymorph of regadenoson and process for preparation thereof APICORE US LLC (US) 2019-08-27 US disclosed
US-20180127452-A1 NOVEL POLYMORPH OF REGADENOSON AND PROCESS FOR PREPARATION THEREOF APICORE US LLC (US) 2018-05-10 US disclosed
US-20180127452-A1 NOVEL POLYMORPH OF REGADENOSON AND PROCESS FOR PREPARATION THEREOF APICORE US LLC (US) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127452-A1 NOVEL POLYMORPH OF REGADENOSON AND PROCESS FOR PREPARATION THEREOF PRPF6, CYP2D6, ADH1A ADORA2A 873/4885ADORA3 674/4885ADORA1 1058/4885
US-10392417-B2 Polymorph of regadenoson and process for preparation thereof CYP2D6, PRPF6, CYP2B6 ADORA2A 702/4885ADORA3 553/4885ADORA1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.